Alexander "Sasha" Stafford
Consultant | Founder & Principal Scientist at Elixis Biosciences and Prodelic Technologies
Strategic Advisory
I partner with VCs, pharma companies, and scaling startups to de-risk and scale high-stakes drug delivery and biomaterials programs. By providing deep technical validation, I help bridge the gap between early-stage innovation and clinical-grade assets through rigorous formulation and platform expertise. My mission is to transform complex research into commercially viable systems that maximize both therapeutic impact and investor ROI.
• Faster, de-risked decision-making for complex investment and R&D pipelines
• More valuable and defensible IP portfolios for global licensing
• Seamless translation of academic breakthroughs into scalable clinical assets
Client-Focused Outcomes
De-Risking Investments
Enabling VCs and pharma partners to make faster, data-driven decisions by providing deep-dive technical due diligence and auditing therapeutic pipelines for manufacturing feasibility.
Maximizing IP Value
Scaling Bio-Platforms
Securing long-term commercial value by converting innovative formulation chemistry into robust, protectable intellectual property ready for global market acquisition.
Accelerating the shift from bench-side research to industrial-scale production through proven CMC strategies and expert technology transfer management.
Targeted Consulting
For Venture Capital
Independent technical audits and platform validation to drive intelligent investment decisions and identify hidden manufacturing risks before commitment.
For Pharma Teams
Engineering target-specific delivery vectors and optimizing complex payloads to ensure clinical readiness and superior therapeutic efficacy.
For Growth Startups
Strategic scientific leadership to align early-stage R&D with regulatory requirements, ensuring a clear path to IND and market exit.
Core Qualifications
- Masters Nanotechnology & Bioengineering - Harvard Extension School
- Certificate in Finance - Golden Gate University
- B.S. Chemistry - UC Santa Cruz
Leveraging 15 years at Harvard’s Wyss Institute, Sasha serves as a dedicated consultant and strategic partner to de-risk and scale high-stakes programs. While maintaining his roles as Founder and Principal Scientist at Elixis Biosciences and Prodelic Technologies, he offers external technical advisory to ensure clinical readiness and commercial viability. By engineering lipid nanoparticles and nasal delivery systems, he secures investor value through IP-protected, scalable platforms. Sasha bridges the gap between early-stage innovation and regulatory excellence, offering the hands-on partnership required to optimize assets for exit and maximize ROI for his consulting clients and industry partners.
Alexander (Sasha) Stafford is a strategic consultant and innovative problem-solver helping biotech entities navigate complex drug delivery and translational hurdles. Drawing on 15 years at the Wyss Institute and his current roles as Founder and Principal Scientist at Elixis Biosciences and Prodelic Technologies, he scales scientific discovery into commercial assets.
Drawing on 15 years within Harvard’s Wyss Institute and his leadership as Founder and Principal Scientist at Elixis and Prodelic Technologies, Sasha offers high-level consulting to bridge the gap between bench science and clinical reality. He specializes in helping clients overcome the friction of moving emerging technologies into production, having successfully led IND-enabling CMC programs and authored foundational patents that secure market position.
Sasha’s consulting value is built on his proven ability to de-risk therapeutic development through rigorous technical validation and regulatory alignment. His deep experience includes establishing cGMP-compliant operations and managing international CMO partnerships to ensure platforms exceed ICH and FDA standards. He serves as an essential partner for those needing to translate academic breakthroughs into industrial-grade assets that maintain scientific integrity and commercial viability.
Working as a collaborative consultant, Sasha partners with cross-functional teams to tackle high-stakes drug delivery challenges head-on. He designs sophisticated biomaterial systems and specialized delivery vehicles that balance scientific precision with patient compliance. By streamlining complex formulation methods, Sasha enables his clients to enhance therapeutic efficacy and achieve superior clinical outcomes on a global scale.
Drug Delivery & Biomaterials
Hydrogels and cryogels; click‑crosslinked alginates; injectable scaffolds; lipid nanoparticles (LNPs); liposomes and micelles; virosomes; PLGA microparticles and scaffolds; mRNA and nucleic‑acid delivery; vaccine depots and combination products.
Regulatory & Translational
ICH/FDA‑aligned method qualification (e.g., ICH Q2(R1)), CMC support for IND submissions, quality management systems, SOP and documentation systems, audit preparation and defense, tech transfer to industry, oversight of CMOs and CROs, safety and compliance programs.
Skills and Expertise
Analytical & Quality
HPLC (reverse‑phase, SEC, GPC, IEC, HILIC, chiral), ELISA, capillary electrophoresis, PAGE and Western blot, IEF, FTIR, rheology, dynamic light scattering, microscopy, flow cytometry, spectroscopic assays, dissolution and stability testing, clinical kit and final product configuration. cGMP laboratory operations, assay development and remediation, method qualification and validation, QC release and stability programs.
Leadership & Collaboration
Team leadership and mentoring of scientists, research associates, and students; cross‑functional project management; interface with clinical, QA, and development teams; industry‑academic partnerships; sponsored research agreements; presentations at scientific meetings and consortia.
